Basis of Presentation (Details) - USD ($) $ in Thousands	Feb. 20, 2020	Mar. 31, 2023	Dec. 31, 2022
Business Acquisition [Line Items]
Contingent consideration liabilities		$ 110,200	$ 111,600
Business combination, consideration transferred, equity interests issued (in shares)	26,844,877
Business combination common stock under contingent value right (in shares)	86,630,633
Progenics
Business Acquisition [Line Items]
Aggregate cash payments percentage	40.00%
Percentage of total contingent consideration under CVRs	19.90%
Business combination contingent value right of total consideration	$ 99,700
Progenics | Cash Payments 2022
Business Acquisition [Line Items]
Contingent consideration liabilities	100,000
Progenics | Cash Payments 2023
Business Acquisition [Line Items]
Contingent consideration liabilities	$ 150,000